PTN

Palatin Technologies Inc New
2.70
-0.05 (-1.82%)
Company Name Stock Ticker Symbol Market Type
Palatin Technologies Inc New PTN AMEX Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.05 -1.82% 2.70 20:00:00
Open Price Low Price High Price Close Price Prev Close
2.75 2.67 2.78 2.70 2.75
more quote information »

Recent News

Date Time Source Heading
3/02/202307:30PRNUSFrontiers in Immunology Publishes Pre-Clinical Study of..
2/28/202307:30PRNUSPalatin Issued Patent on Vyleesi® (Bremelanotide Injection)..
2/15/202308:27EDGARCurrent Report Filing (8-k)
2/15/202307:30PRNUSPalatin Reports Second Quarter Fiscal Year 2023 Financial..
2/14/202316:50EDGARQuarterly Report (10-q)
2/14/202313:20EDGARStatement of Ownership (sc 13g)
2/10/202307:30PRNUSPalatin to Report Second Quarter Fiscal Year 2023 Results;..
1/19/202307:30PRNUSPalatin Initiates Enrollment in the Phase 2 Bremelanotide..
1/18/202307:30PRNUSPalatin Receives $4.7 Million of Non-Dilutive Funding
1/10/202307:30PRNUSFrontiers in Immunology Publishes Pre-Clinical Study of..
1/05/202307:30PRNUSPalatin Announces Preliminary Second Quarter Fiscal 2023..
12/28/202210:30EDGARAmended Statement of Changes in Beneficial Ownership (4/a)
12/28/202210:30EDGARAmended Statement of Changes in Beneficial Ownership (4/a)
12/23/202217:31EDGARStatement of Changes in Beneficial Ownership (4)
11/15/202207:05TRMNLadenburg Thalmann & Co. Sticks to Their Buy Rating for..
11/14/202216:51EDGARQuarterly Report (10-q)
11/14/202208:02EDGARCurrent Report Filing (8-k)
11/14/202207:30PRNUSPalatin Reports First Quarter Fiscal Year 2023 Financial..
11/09/202217:16PRNUSPalatin to Report First Quarter Fiscal Year 2023 Results;..
11/02/202217:08EDGARCurrent Report Filing (8-k)
11/02/202210:37EDGARProspectus Filed Pursuant to Rule 424(b)(5) (424b5)
10/31/202209:30PRNUSPalatin Announces $10 Million Registered Direct Offering
10/25/202217:02EDGARStatement of Changes in Beneficial Ownership (4)
10/24/202217:32PRNUSPalatin Presents PL8177 Data at American College of..
10/20/202207:30PRNUSFirst Patient Enrolled in Palatin's Phase 2 study of PL8177..
10/17/202210:25TRMNH.C. Wainwright Reaffirms Their Buy Rating on Palatin..
10/17/202207:30PRNUSPalatin Announces Publication of Vyleesi® (bremelanotide)..
10/13/202207:30PRNUSPalatin Announces Preliminary First Quarter Fiscal 2023..
9/29/202215:45PRNUSPalatin Announces Presentation at the Eyecelerator@AAO 2022..
9/29/202213:31PRNUSPalatin to Participate in Ladenburg Thalmann Healthcare..
9/27/202206:03EDGARNotice of Effectiveness (effect)
9/26/202215:57EDGARSecurities Registration: Employee Benefit Plan (s-8)
9/23/202209:27EDGARSecurities Registration Statement (simplified Form) (s-3/a)
9/23/202207:45TRMNLadenburg Thalmann & Co. Sticks to Their Buy Rating for..
9/22/202216:32EDGARAnnual Report (10-k)
9/22/202212:05TRMNH.C. Wainwright Sticks to Their Buy Rating for Palatin..
9/22/202208:48EDGARCurrent Report Filing (8-k)
9/22/202207:30PRNUSPalatin Reports Fourth Quarter and Fiscal Year 2022..
9/19/202216:15PRNUSPalatin to Report Fourth Quarter and Fiscal Year End 2022..
9/08/202212:05TRMNH.C. Wainwright Sticks to Their Buy Rating for Palatin..
9/08/202207:30PRNUSPalatin Announces Initiation of Patient Recruitment for..
8/31/202208:01EDGARCurrent Report Filing (8-k)
8/19/202216:31EDGARCurrent Report Filing (8-k)
8/19/202207:30PRNUSPalatin Announces Intent to Effect Reverse Stock Split
8/16/202213:45TRMNLadenburg Thalmann & Co. Reaffirms Their Buy Rating on..
8/16/202210:55TRMNH.C. Wainwright Reaffirms Their Buy Rating on Palatin..
8/16/202207:30PRNUSPalatin Reports Positive Interim Analysis in Phase 3 Pivotal..
7/26/202207:30PRNUSPalatin Announces Preliminary Fourth Quarter Vyleesi® Net..
6/28/202216:31EDGARStatement of Changes in Beneficial Ownership (4)
6/28/202216:31EDGARCurrent Report Filing (8-k)